To improve the website's functionality, we use cookies, including third-party cookies. Read our Privacy Policy for more information

I Agree

Peptide-based Metabolic Disorders Therapeutics Market

Peptide-based Metabolic Disorders Therapeutics Market By Drug (Liraglutide, Exenatide), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), & Region - Global Market Insights 2023 to 2033

Analysis of Peptide-based Metabolic Disorders Therapeutics Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more

Peptide-based Metabolic Disorders Therapeutics Market Outlook (2023 to 2033)

Global demand for peptide-based metabolic disorder therapeutics is forecasted to increase at a stellar CAGR of 12% from 2023 to 2033. As a result, the global peptide-based metabolic disorder therapeutics market is projected to attain a valuation of US$ 77.9 billion by the end of 2033, up from its current size of US$ 25 billion.

Sedentary lifestyle adoption has catalyzed the incidence of metabolic disorders and also resulted in a high prevalence of health complications among individuals across the world. Growing digitization, poor eating habits, lack of physical activity, and increasing focus on health and fitness are other prospects that alter the demand outlook for metabolic disorder therapeutics and treatments on a global level. The aforementioned factors are also estimated to bolster demand for peptide-based cardiovascular therapeutics over the coming years.

Supportive government initiatives to bolster healthcare research and infrastructure development are projected to influentially boost demand for peptide-based therapies and peptide-based infection therapeutics across the forecast period. Growing awareness regarding the benefits of peptides and increasing focus on peptide-based treatment research by pharmaceutical and biotechnology companies are also projected to boost sales of peptide-based metabolic disorder treatment drugs through 2033.

 “Market Benefiting from Growing Investments in Research & Development”

The past few years have depicted how the incidence of chronic diseases has increased dramatically on a global level and this is a major trend that has resulted in increased research and development activity in the healthcare industry. Governments across the world are investing in expanding their research scope to deal with the advent of increasingly treacherous chronic ailments and protect the world from them. The high use of peptide-based cancer therapeutics to treat cancer is also expected to open up new opportunities for peptide-based treatment providers in the future.

On the contrary, the widespread availability of alternative therapeutics and treatments for metabolic disorders is projected to have an inhibiting effect on the overall peptide-based metabolic disorders therapeutics market evolution going forward. Supply chain management issues and stringent safety regulations implemented by regulatory bodies are also anticipated to emerge as major challenges for upcoming and established market players alike.

Report Attributes

Details

Peptide-based Metabolic Disorders Therapeutics Market Size (2023)

US$ 25 Billion

Projected Market Value (2033F)

US$ 77.9 Billion

Global Market Growth Rate (2023 to 2033)

12% CAGR

Online Pharmacies Segment Growth Rate (2023 to 2033)

11.5% CAGR

North America Market Growth Rate (2023 to 2033)

10.6% CAGR

Key Companies Profiled

  • Eli Lilly Company
  • Ipsen S.A
  • PolyPeptide Group
  • Bachem Holding AG.
  • CordenPharma International
  • PolyPeptide Group
  • Novo Nordisk A/S
  • Merck & Co. Inc.
  • Teva Pharmaceutical Industries Ltd.
  • AstraZeneca PLC

Don't Need a Global Report?

Save 40% on Country & Region specific reports

Which Key Prospect Will Determine the Peptide-based Metabolic Disorders Therapeutics Market Growth Path?

“Increasing Incidence of Metabolic Disorders”

Adoption of sedentary lifestyles and poor dietary choices have resulted in the early onset of several metabolic disorders in people across the world and this is expected to prominently influence sales of peptide-based metabolic disorder therapeutics across the forecast period. Some of the most common metabolic disorders in the world are Type 1 and 2 diabetes, obesity, cardiovascular disorders, and kidney diseases among others.

  • As per the World Obesity Atlas 2022 published by the World Obesity Federation, nearly 1 billion people are anticipated to be suffering from obesity issues across the world by 2030. 1 in 7 men and 1 in 5 women are projected to be obese by the end of 2030.

Increasing obesity also results in an increased risk of type 1 and type 2 diabetes among individuals and thus, is projected to bolster demand for peptide-based metabolic disorder therapeutics in the long run.

Peptide Based Metabolic Disorders Therapeutics Market Forecast by Fact.MR

Peptide-based Metabolic Disorders Therapeutics Market

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

What is the Start-up Ecosystem for the Peptide Therapeutics Space?

“New Companies Focusing on Innovation & Capital Raising to Launch Novel Products”

New peptide-based metabolic disorder therapeutics companies are focusing on increasing their investments in research and development of innovative peptide therapies for metabolic disorders and other diseases.

  • ResQ Biotech, a start-up company based in the United States is focusing on developing unique peptide-based treatments by harnessing this potential from bacteria. The organization focuses on protein misfolding and certain incurable conditions such as amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease.

Peptide-based metabolic disorder therapeutics start-ups are also focusing on collaborations, partnerships, and mergers to fast-track the development of innovative products and bolster their presence in the global competitive landscape through 2033.

  • In January 2023, Nimble Therapeutics, a biotech organization spun out from Roche collaborated and executed a license agreement with Genetech, an arm of Roche Group. The collaboration is expected to focus on the discovery of peptide therapies for the treatment of various diseases.

Incoming market players are also focusing on bagging new capital and finance that will help them contend with established peptide-based metabolic disorder therapeutics companies operating in the current competitive landscape.

  • In December 2020, Peptilogics, a biotechnology organization focused on developing and designing novel peptide therapeutics announced that it had closed its Series B financing round with a total of US$ 35.4 billion. The raise was led by Presight Capital along with a new investor called Founders Fund.

More insights regarding pricing trends, product standards, new developments, local supply, and global demand have been discussed extensively in this updated peptide-based metabolic disorders therapeutics market research report by Fact.MR, a market research and competitive intelligence provider.

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

Country-wise Insights

Why Should Peptide-based Metabolic Disorder Therapeutics Suppliers Invest in Asia Pacific?

“Supportive Initiatives to Promote Investments in Healthcare Industry”

The advent of several chronic diseases and the high incidence of metabolic disorders in Asian countries had led to increasing investments in healthcare infrastructure development by governments and regulatory authorities alike. The aforementioned factor is ascribed to primarily augment demand for peptide-based metabolic disorder therapeutics over the next ten years.

India, Japan, Korea, and China are expected to be prime markets in the APAC region throughout the forecast period. Rising foreign direct investments, the presence of several pharmaceutical manufacturing companies, and supportive government initiatives are other prospects that are slated to uplift peptide-based metabolic disorder therapeutics demand in the aforementioned countries through 2033.

What Aspects Will Alter the Demand for Peptide-based Metabolic Disorder Therapeutics in European Countries?

“Increasing Awareness Regarding Metabolic Disorders and Growing Senescent Population”

Focus on health and fitness has increased noticeably in the European region owing to growing awareness among the general population, which is projected to create an opportune setting for peptide-based metabolic disorder therapeutics companies in the future. The United Kingdom, Germany, and Italy are anticipated to be prime markets for peptide-based metabolic disorder therapeutics in the European region.

Increasing healthcare expenditure, rising awareness regarding the efficacy of peptide-based therapeutics, and supportive initiatives to promote healthcare research and development activity are other aspects that shape peptide-based metabolic disorders therapeutics market evolution in Europe. The increasing interest of several European biotechnology companies in peptide-based drugs and treatment procedures is also expected to offer lucrative business scope in the future.

Which Country is the Most Profitable Market in North America?

“United States to Offer Highly Remunerative Business Opportunities”

The United States is projected to be the most attractive market for peptide-based metabolic disorder therapeutics in the North American region across the forecast period owing to increasing investments in research and development of medical treatments and rapid adoption of novel treatment procedures. High healthcare expenditure, the growing prevalence of obesity, and increasing investments in peptide-based therapy and treatment research by several biotech companies in the United States are other aspects that could potentially uplift peptide-based metabolic disorder therapeutics demand in the future.

Supportive government initiatives to promote healthcare R&D and the presence of key pharmaceutical companies in the country are also expected to boost market development through 2033. Increasing awareness regarding the benefits associated with peptide-based drugs and therapies is also projected to play a crucial role in augmenting shipments of peptide-based metabolic disorder therapeutics over the next ten years.

Category-wise Insights

Which Drug Type is Widely Accepted in Most Parts of the World?

“Liraglutide Class of Drugs to Account for Dominant Market Share”

Based on drug, the peptide-based metabolic disorders therapeutics market is segmented into liraglutide, exenatide, and others.

The liraglutide segment accounts for a significant market share at present and is projected to maintain a similar stance over the next ten years. Liraglutide is a glucagon-like peptide-1 receptor used in the development of anti-diabetic medication, treatment of obesity, and other types of human disorders.

High incidences of obesity and type 2 diabetes across the world are other prospects that are anticipated to uplift demand in this segment throughout the forecast period. Demand for exenatide and other drugs is expected to rise at a higher CAGR than that of liraglutide over the coming years, which can be ascribed to growing investments in drug discovery and drug development processes.

Where Will Demand for Peptide-based Metabolic Disorder Therapeutics Shine Bright?

“Hospital Pharmacies Accounting for High Peptide-based Metabolic Disorder Therapeutics Sales”

Based on distribution channel, the peptide-based metabolic disorders therapeutics market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.

Increasing rate of hospitalization and growing investments in the development of healthcare infrastructure are prime factors that are driving peptide-based metabolic disorder therapeutics demand in hospital pharmacies at present. The segment is anticipated to account for a dominant share of the global marketplace throughout the forecast period.

Meanwhile, shipments of peptide-based metabolic disorder therapeutics through online pharmacies are estimated to rise at a phenomenal CAGR of around 11.5% owing to increasing penetration of the internet and the growing popularity of e-Commerce among the general population of the world. Retail pharmacies are expected to witness a moderate hike in peptide-based metabolic disorder therapeutic sales through 2033.

Competitive Landscape

Peptide-based metabolic drug providers are focusing on obtaining new approvals from regulatory authorities to fast-track product launches and optimize sales potential.

  • In January 2023, the United States Food and Drug Administration (FDA) approved the use of Rybelsus, a drug for diabetic patients by Novo Nordisk as a first-line treatment for people suffering from type 2 diabetes. Drug providers in the United States can now directly prescribe the aforementioned drug to diabetic people because of this new approval.

Segments of Peptide-based Metabolic Disorders Therapeutics Industry Research

  • By Drug :

    • Liraglutide
    • Exenatide
    • Others
  • By Distribution Channel :

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region :

    • North America
    • Latin America
    • Europe
    • APAC
    • MEA

- Premium Report Details -

Peptide-based Metabolic Disorders Therapeutics Market
  • FACT187MR
  • Jan-2023
  • Healthcare
  • 170 Pages
  • 145 Tables
  • 45 Figures

- Let's Connect -

Talk To an Expert Today Connect

- Get Started -

Get insights that lead to new growth opportunities

Buy Now

Get A Special pricing for start-ups and universities

Enquiry Before Buying

- Humble, Yet Honored -

Our prestigious clients

- Research Methodology -

An Adaptive Approach to Modern-day Research Needs

Get Methodology

- FAQs -

The global peptide-based metabolic disorders therapeutics market stands at US$ 25 billion in 2033.

By 2033-end, demand for peptide-based metabolic disorder therapeutics is projected to reach a market value of US$ 77.9 billion.

Peptide-based metabolic disorder therapeutics demand is forecasted to increase at 12% CAGR through 2033.

Peptide-based metabolic disorder therapeutics demand through online pharmacies is projected to rise at 11.5% CAGR.

PolyPeptide Group, Novo Nordisk A/S, Merck & Co. Inc., and AstraZeneca PLC are key market players profiled in this study.

Exclusive Report

Need An Exclusive Report For Your Unique Requirement?

Google translate